Evidence map›Paper›PMID 31969710›Full record

ArticleNature2020

Targeting of temperate phages drives loss of type I CRISPR-Cas systems.

Clare Rollie, Anne Chevallereau, Bridget N J Watson, Te-Yuan Chyou, Olivier Fradet, Isobel McLeod, Peter C Fineran, Chris M Brown, Sylvain Gandon, Edze R Westra

Erratum issuedAbstract read
In one paragraph

Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Bacterial immune systems.Antonie van Leeuwenhoek · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Phage defence-system abundances vary across environments and increase with viral density.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Characterization of CRISPR-Cas Systems inPathogens (Basel, Switzerland) · 2024
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Clare Rollie *ESI, Biosciences, University of Exeter, Penryn, UK. C.Rollie@exeter.ac.uk.
Anne Chevallereau *ESI, Biosciences, University of Exeter, Penryn, UK. A.Chevallereau@exeter.ac.uk.
Bridget N J WatsonESI, Biosciences, University of Exeter, Penryn, UK.
Te-Yuan ChyouDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
Olivier FradetESI, Biosciences, University of Exeter, Penryn, UK.
Isobel McLeodESI, Biosciences, University of Exeter, Penryn, UK.
Peter C FineranDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Chris M BrownDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
Sylvain GandonCEFE, Université de Montpellier, CNRS, EPHE, IRD, Université Paul Valéry Montpellier 3, Montpellier, France.
Edze R WestraESI, Biosciences, University of Exeter, Penryn, UK. E.R.Westra@exeter.ac.uk.

Funding

European Research Council 714478
6 · The paper itself

Abstract

On infection of their host, temperate viruses that infect bacteria (bacteriophages; hereafter referred to as phages) enter either a lytic or a lysogenic cycle. The former results in lysis of bacterial cells and phage release (resulting in horizontal transmission), whereas lysogeny is characterized by the integration of the phage into the host genome, and dormancy (resulting in vertical transmission)

Indexed as

CRISPR-Cas SystemsBacteriaBacteriophagesGene Expression Regulation, ViralLysogenyProphages

Identifiers

PMID31969710
PMCPMC7007301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.